2013 Annual Meeting | Criteria for Stopping and Starting Multiple Sclerosis Therapy

Date Sunday 03/17/13

Time 06:30 AM - 09:30 AM Add To Calendar

Session Format This program will be presented both in-person and online

On Demand This program is not expected to be available in the meeting's On Demand product.

Event Type Extended Seminar

Director(s) Mark Keegan, MD, FAAN

Topic(s)

Learning Objectives Participants should be familiar with some of the variables and difficulties involved in deciding when to start treatment with disease-modifying therapies in RRMS and when to stop such treatments in persons possibly no longer benefiting from them.

CME Available No CME available

Core Competencies Patient Care & Procedural Skills, Medical Knowledge

Recommended Audience Trainee, General Neurologist, Specialist Neurologist

Teaching Styles Case-based, Didactic, Audience Participation

Event Timeline
06:30 AM - 07:10 AM		Clinical Importance of Relapses in Multiple Sclerosis Helen Tremlett, PhD, BPharm
07:10 AM - 07:50 AM		When to Start Disease Modifying Therapy in RRMS Brian G. Weinshenker, MD, FAAN
07:50 AM - 08:10 AM		Discussion
08:10 AM - 08:30 AM		Break
08:30 AM - 09:10 AM		Stopping and Changing MS Therapies Mark Keegan, MD, FAAN
09:10 AM - 09:30 AM		Questions and Answers

Faculty Disclosures
Brian G. Weinshenker, MD, FAAN	Dr. Weinshenker has received personal compensation in the range of $500-$4,999 for serving as a Consultant for CANbridge Pharmaceuticals. Dr. Weinshenker has received personal compensation in the range of $0-$499 for serving as a Consultant for CALIBR. Dr. Weinshenker has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Horizon. Dr. Weinshenker has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. Dr. Weinshenker has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche Group (Chugai, Genentech, Roche). Dr. Weinshenker has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for UCB Pharmaceuticals. Dr. Weinshenker has received research support from Guthy Jackson Charitable Foundation. Dr. Weinshenker has received intellectual property interests from a discovery or technology relating to health care.
Mark Keegan, MD, FAAN	Dr. Keegan has received personal compensation in the range of $500-$4,999 for serving as a Consultant for EMD Serono. Dr. Keegan has received publishing royalties from a publication relating to health care. Dr. Keegan has received publishing royalties from a publication relating to health care.
Helen Tremlett, PhD, BPharm	Dr. Tremlett has nothing to disclose.

��ɫ��

��ɫ��